Maximizing CRISPR/Cas9 phenotype penetrance applying predictive modeling of editing outcomes in Xenopus and zebrafish embryos
暂无分享,去创建一个
M. Horb | A. Zorn | T. Naert | Nikko-Ideen Shaidani | A. Boel | P. Coucke | A. Willaert | Marcin Wlizla | K. Vleminckx | N. Edwards | S. Demuynck | D. Tulkens | Marjolein Carron | M. Carron
[1] J. Zuber,et al. Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles , 2020, Nature Methods.
[2] Kutubuddin A Molla,et al. Predicting CRISPR/Cas9-Induced Mutations for Precise Genome Editing. , 2020, Trends in biotechnology.
[3] T. Haaf,et al. Homozygous Null TBX4 Mutations Lead to Posterior Amelia with Pelvic and Pulmonary Hypoplasia. , 2019, American journal of human genetics.
[4] Ashley M. Jacobi,et al. Highly Efficient CRISPR-Cas9-Based Methods for Generating Deletion Mutations and F0 Embryos that Lack Gene Function in Zebrafish. , 2019, Developmental cell.
[5] Xiaobing Shi,et al. De novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens , 2019, Nature Communications.
[6] Ben Lehner,et al. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy , 2019, Nature Genetics.
[7] Nicholas A. Rossi,et al. Inference of CRISPR Edits from Sanger Trace Data , 2019, bioRxiv.
[8] Carla M. Mann,et al. The Gene Sculpt Suite: a set of tools for genome editing , 2019, Nucleic Acids Res..
[9] M. Horb,et al. Xenopus Resources: Transgenic, Inbred and Mutant Animals, Training Opportunities, and Web-Based Support , 2019, Front. Physiol..
[10] M. van de Rijn,et al. CRISPR-NSID: an in vivo CRISPR/Cas9 negative selection screen reveals EZH2 as a druggable dependency factor in a genetic desmoid tumor model , 2019, bioRxiv.
[11] Xiaobing Shi,et al. De novo identification of essential protein domains from CRISPR-Cas9 tiling-sgRNA knockout screens , 2019, Nature Communications.
[12] Troy J. Pells,et al. Xenbase: Facilitating the Use of Xenopus to Model Human Disease , 2019, Front. Physiol..
[13] P. Van Vlierberghe,et al. Xenopus tropicalis: Joining the Armada in the Fight Against Blood Cancer , 2019, Front. Physiol..
[14] Djork-Arné Clevert,et al. PAVOOC: designing CRISPR sgRNAs using 3D protein structures and functional domain annotations , 2018, bioRxiv.
[15] William Stafford Noble,et al. Massively parallel profiling and predictive modeling of the outcomes of CRISPR/Cas9-mediated double-strand break repair , 2018, bioRxiv.
[16] Andrew R. Bassett,et al. Predicting the mutations generated by repair of Cas9-induced double-strand breaks , 2018, Nature Biotechnology.
[17] David K. Gifford,et al. Predictable and precise template-free CRISPR editing of pathogenic variants , 2018, Nature.
[18] Carla M. Mann,et al. Robust activation of microhomology-mediated end joining for precision gene editing applications , 2018, PLoS genetics.
[19] T. Naert,et al. CRISPR/Cas9 disease models in zebrafish and Xenopus: The genetic renaissance of fish and frogs. , 2018, Drug discovery today. Technologies.
[20] Maryam Clausen,et al. Decoding non-random mutational signatures at Cas9 targeted sites , 2018, Nucleic acids research.
[21] Rahul C. Deo,et al. A Rapid Method for Directed Gene Knockout for Screening in G0 Zebrafish. , 2018, Developmental cell.
[22] H. Kayserili,et al. RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6 , 2018, Nature.
[23] James C. Smith,et al. Innate Immune Response and Off-Target Mis-splicing Are Common Morpholino-Induced Side Effects in Xenopus , 2018, Developmental cell.
[24] Wouter Steyaert,et al. BATCH-GE: Analysis of NGS Data for Genome Editing Assessment. , 2018, Methods in molecular biology.
[25] T. Naert,et al. Methods for CRISPR/Cas9 Xenopus tropicalis Tissue-Specific Multiplex Genome Engineering. , 2018, Methods in molecular biology.
[26] M. Horb,et al. Tissue-Specific Gene Inactivation in Xenopus laevis: Knockout of lhx1 in the Kidney with CRISPR/Cas9 , 2017, Genetics.
[27] Deniz M. Ozata,et al. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion , 2017, Genome Biology.
[28] Adam Lavertu,et al. Frameshift indels introduced by genome editing can lead to in-frame exon skipping , 2017, PloS one.
[29] M. Getwan,et al. Toolbox in a tadpole: Xenopus for kidney research , 2017, Cell and Tissue Research.
[30] T. Naert,et al. TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models , 2017, Genesis.
[31] D. Deforce,et al. CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis , 2016, Scientific Reports.
[32] A. May,et al. DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks. , 2016, Molecular cell.
[33] B. Menten,et al. BATCH-GE: Batch analysis of Next-Generation Sequencing data for genome editing assessment , 2016, Scientific Reports.
[34] Charles E. Vejnar,et al. CRISPRscan: designing highly efficient sgRNAs for CRISPR/Cas9 targeting in vivo , 2015, Nature Methods.
[35] Marcus Krüger,et al. Genetic compensation induced by deleterious mutations but not gene knockdowns , 2015, Nature.
[36] J. Kinney,et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains , 2015, Nature Biotechnology.
[37] C. Betsholtz,et al. Reverse genetic screening reveals poor correlation between morpholino-induced and mutant phenotypes in zebrafish. , 2015, Developmental cell.
[38] Hidemasa Bono,et al. CRISPRdirect: software for designing CRISPR/Cas guide RNA with reduced off-target sites , 2014, Bioinform..
[39] Xiaohui Xie,et al. Biallelic genome modification in F0 Xenopus tropicalis embryos using the CRISPR/Cas system , 2013, Genesis.
[40] Marilyn Fisher,et al. Simple and efficient CRISPR/Cas9‐mediated targeted mutagenesis in Xenopus tropicalis , 2013, Genesis.
[41] Jeffry D. Sander,et al. Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.
[42] Jeffry D. Sander,et al. Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.